May 5, 2020 / 11:52 AM / a month ago

BRIEF-Akebia Therapeutics Reports Qtrly Loss Per Share Of $0.47

May 5 (Reuters) - Akebia Therapeutics Inc:

* AKEBIA ANNOUNCED POSITIVE TOP-LINE RESULTS FROM GLOBAL PHASE 3 PROGRAM OF VADADUSTAT FOR TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULT PATIENTS ON DIALYSIS; REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

* Q1 REVENUE $88.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $77.5 MILLION

* COMPANY’S CASH RUNWAY EXTENDS WELL INTO 2021

* QTRLY LOSS PER SHARE $0.47 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below